IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
- Status
- SUSPENDED
- Phase
- PHASE1
Clinical Trials Related to Fludarabine
Related studies linked through entity extraction aliases.
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
- Status
- RECRUITING
- Phase
- PHASE1
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Status
- RECRUITING
- Phase
- PHASE3
Twice-per-weekSelinexor, 2 Days Melphalan
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
- Status
- WITHDRAWN
- Phase
- PHASE1
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Status
- RECRUITING
- Phase
- PHASE2